First, we did not use NSCLC cell lines with EGFR L858R mutation, although we showed that ZEB1 was highly expressed in tumor specimens from NSCLC patients with EGFR L858R mutation after gefitinib resistance. This evidence concerns the gene ZEB1 and non-small cell lung carcinoma.